BioCryst Pharmaceuticals | BCRX - 営業経費





営業経費 変化する 日付
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Chugai Pharma JPY 201.8B 21.07B 2026-09
Daiichi Sankyo JPY 483.8B 5.85B 2026-09
DBV Technologies USD 64.8M 16.9M 2026-09
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 13.04B 9.09B 2026-09
GlaxoSmithKline GBP 6.03B 227M 2026-09
Glaxosmithkline GBP 6.76B 1.42B 2026-09
Incyte USD 5.64B 4.67B 2026-09
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 211.54M 15.12M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09